GCIAgronomics ups stake in VitroLabs
The AIM-listed investment firm announced that it participated in a $1 million SAFE (Simple Agreement For Future Equity) subscription into VitroLabs.
Agronomics said the subscription would increase its potential equity position from 3.79% to 6.15%, subject to converting at the valuation cap of US$ 25 million at the time of VitroLab's Series A.
Agronomics first invested $1.5 million into Vitrolabs in 17 October 2019, through a $1.5 million subscription.
Agronomics shares were trading flat on Thursday at 7.625p each
VitroLabs is a clean cellular-agriculture company creating slaughter-free, environmentally friendly leather.
It was founded by Ingvar Helgason and Dr Dusko Ilic in 2016. Dr. Ilic is an experienced stem cell biologist from King's College, London, with technical expertise in tissue engineering and stem cell biology.
"We continue to be impressed by the strong developments VitroLabs is making as the only company in the world to be using this technology to create real leather, without the requirements of raising animals and the issues surrounding animal welfare, sustainability and efficiency” said Richard Reed, Chairman of Agronomics.
He added: “We are excited for the next 12 months where we expect to see VitroLabs launch their first leather goods to the market."
Agronomics said it funded the investment with cash from its existing resources.
Ingvar Helgason, Founder and CEO of VitroLabs commented: "We are excited to continue working with the Agronomics team whose partnership has been invaluable as we continue developing our technology and platform.”
“There is a huge need for a source of real, sustainable leather and we're glad to have Agronomics' continued support as we solve this huge problem."
Agronomics makes investments in the fields of cellular agriculture and synthetic biology, with an emphasis on environmentally friendly alternatives to the traditional production of animal-derived products.
Follow News & Updates from Agronomics here:
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.